Compare Enovix Corporation (ENVX) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enovix Corporation vs Gilead Sciences, Inc. — how do they compare? Enovix Corporation trades at $2.54 (market cap $561.79M), while Gilead Sciences, Inc. trades at $147 (market cap $182.09B). The key difference: Gilead Sciences, Inc. is far larger — about 324.1× Enovix Corporation's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Enovix Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enovix Corporation for 11 Days and Gilead Sciences, Inc. for 111 Days on average.
| ENVX | GILD | |
|---|---|---|
Market Cap | $561.79M | $182.09B |
Volume | 5,898,906 | 4,960,247 |
Sector | Industrials | Health |
52-Week High | $13.19 | $155.80 |
52-Week Low | $2.50 | $116.74 |
Typical Hold Time | 11 Days | 111 Days |
Enterprise Value | $623.49M | $205.15B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVX trades at $2.55, down 5.56% today, reflecting ongoing investor concerns despite recent earnings beats. The stock shows bearish technical signals with negative moving averages and oscillators. Fundamentally, the company continues to burn cash with a net income margin of -473.89% in 2026, though revenue growth remains positive at 32% year-over-year. Recent CEO transition and strategic focus on defense battery manufacturing create uncertainty about execution.
The outlook remains challenging with significant cash burn and negative profitability, though analyst consensus is bullish with a $10.75 price target representing 321% upside. Key risks include execution challenges, high cash consumption, and competitive pressures in the battery sector. The company's $552 million cash position provides runway but requires successful commercialization to justify valuation.
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Enovix Corporation
Enovix designs and manufactures advanced silicon-anode lithium-ion batteries. Its technology aims to provide high energy density and improved performance for mobile devices and consumer electronics.
Read more on ENVX →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
